PURA - Puration Sets Closing Date For Acquisition To Expand CBD Beverage Bottling In Europe
November 08 2019 - 2:35PM
InvestorsHub NewsWire
PURA – Puration Sets Closing Date
For Acquisition To Expand CBD Beverage Bottling In Europe
Dallas, TX -- November 8, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced a closing date of November 14,
2019 has been set to finalize the acquisition in Germany
previously announced under a letter of intent (LOI). The
acquisition scheduled to close next Thursday is intended to
establish a bottling capacity in Europe for PURA’s CBD
beverages. The acquisition initiative was driven by PURA
recently signing a distribution
agreement in
Europe for its EVERx CBD Sports Water with other CBD infused
beverages to follow. The initial European distribution
agreement is estimated to add $4 million in sales next year.
Management indicates that the potential of European distribution
beyond the initial $4 million projection warrants the establishment
of a local bottling capacity. The European market for CBD is
projected to reach nearly US $17 billion
by 2023. The bottling expansion in Europe
is part of a bigger plan to expand bottling in Canada and Latin
America. A second LOI to make a similar acquisition for the
Latin American CBD beverage market is anticipated to be announced
next week in addition to the German acquisition closing next
week.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024